Immunotherapy Continues to Advance in Head and Neck Cancer

Source: http://www.onclive.com Author: Megan Garlapow, PhD Concomitant administration of motolimod with cetuximab (Erbitux) increases the innate and adaptive immune response in the blood and the tumor microenvironment in head and neck squamous cell carcinoma (HNSCC), overcoming negative prognostic biomarkers of cetuximab therapy alone, according to the biomarker data from a recent phase Ib clinical […]

from #Medicine-SfakianakisAlexandros via o.lakala70 on Inoreader http://ift.tt/1nck3dQ
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1oTiT8W
via IFTTT